<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056195</url>
  </required_header>
  <id_info>
    <org_study_id>OSCO-P2101</org_study_id>
    <nct_id>NCT04056195</nct_id>
  </id_info>
  <brief_title>Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oscotec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oscotec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed
      to respond or relapsed after prior therapy, with a platelet count &lt;30,000/µL. Patient will be
      randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and
      placebo; administered orally twice a day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the efficacy, safety, tolerability,pharmacokinetics (PK), and
      pharmacodynamics (PD) of select (200 mg BID and 400 mg BID) doses of SKI-O-703 in persistent
      and chronic ITP patients who have failed to respond or relapsed after prior therapy, with a
      platelet count &lt;30,000/µL. on 2 occasions at least 7 days apart with the confirmatory count
      on the first day of treatment.

      subjects will participate in 3 treatment groups (24 subjects in each of the active treatment
      groups and 12 subjects in the placebo group). The total study duration will be 20 weeks per
      subject, which consists of up to 4 weeks of screening period, 12 weeks of treatment period,
      and 4 weeks of follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Response</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Platelet count &gt;= 30,000/µL and doubling the baseline (average of 2 previous counts)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to Discontinuation</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding score</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Measured by Immune thrombocytopenic purpura (ITP) bleeding score (Br. J. Haematol 2007;138(2): 245-8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Measured by the SF-36 score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules of placebo during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI-O-703</intervention_name>
    <description>The SKI-O-703 capsules will contain 100 mg of drug substance.</description>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo capsules are filled with microcrystalline cellulose.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary ITP (persistent or chronic)

          -  Failed to respond or relapsed after at least 1 prior therapy, with a platelet count of
             &lt;30,000/µL on 2 occasions at least 7 days apart with the confirmatory count on the
             first day of treatment

          -  Adequate hematologic, hepatic, and renal function

          -  ECOG performance status of 0, 1, or 2

          -  Male and female subjects, the subject and their partners of childbearing potential
             agree to use medically acceptable methods of contraception during the study and for 6
             months following discontinuation of study drug (excluding women who are not of
             childbearing potential and men who have been sterilized. Men who have been sterilized
             should be confirmed to have negative sperm count on 2 consecutive occasions.)

          -  Male subjects agree not to donate sperm for 90 days after the last dose of study drug

          -  Female subjects have negative pregnancy tests at Screening.

        Exclusion Criteria:

          -  History of current, active malignancy requiring or likely to require chemotherapeutic
             or surgical treatment during the study, with the exception of non-melanoma skin
             cancer, carcinoma in situ of the cervix, and localized prostate cancer managed by
             active surveillance

          -  Transfusion with blood or blood products or plasmapheresis within 2 weeks before the
             first administration of study drug

          -  History of known inherited coagulopathy, or recent arterial or deep venous thrombosis
             within the preceding 6 months

          -  Change in corticosteroid or immunosuppressant dose within 2 weeks prior to Day 1

          -  Treatment with thrombopoietin receptor agonists within 2 weeks before Day 1

          -  Treatment with rituximab or splenectomy within the 8 weeks prior to Day 1

          -  Treatment with intravenous immunoglobulins (IVIGs) within 4 weeks prior to Day 1

          -  Acute infection requiring oral antibiotics within 2 weeks

          -  Infections requiring intravenous antibiotics or hospitalization within 3 months

          -  Positive test results at Screening for human immunodeficiency virus, hepatitis B
             surface antigen, or hepatitis C virus antibody or positive result for hepatitis B core
             antibody with a negative result for hepatitis B surface antigen

          -  Received live vaccine within 28 days prior to Day 1 or plan to receive one during the
             study

          -  History or presence of any gastrointestinal, hepatic, or renal disease or any other
             condition known to interfere with the absorption, distribution, metabolism, or
             excretion of drugs

          -  Uncontrolled hypertension

          -  Subject had 12-lead electrocardiogram (ECG) findings of corrected QT interval by
             Fridericia formula (QTcF) &gt; 450 msec (males) or &gt; 470 msec (females), cardiac
             arrhythmias, or clinically significant cardiac or ECG abnormalities

          -  Subject received any investigational medication within 30 days or 5 half-lives -
             Concomitant use of any anticoagulants and platelet aggregation inhibiting drugs
             including aspirin (within 14 days of planned dosing through end of follow-up)

          -  Female subject who is currently pregnant or breastfeeding

          -  Prior treatment with a SYK inhibitor

          -  Planned surgery in the time frame of the dosing period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information</last_name>
    <phone>please email</phone>
    <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site#</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California, 1441 Eastlake Ave.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, 2301 Erwin Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>22705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras, Department of Internal Medicine, Hematology Division, Rio Patra</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laiko General Hsoptial of Athens, 16 Sevastoupoleos Street</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa, Mezourlo</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgios Papanikolaou General Hospital of Thessaloniki, Exohi</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital, 164 world Cup-ro, Yeongtong-gu</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - PPDS, 88 Olympic-ro 43-gil, Songpa-gu</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClincialTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center PPDS, 81 Irwon-dong Gangnam-gu</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, 101 Daehak-ro, Jongno-gu</name>
      <address>
        <city>Soeul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrials.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System - PPDS, 50-1 Yonsei-Ro, Seodaemun-Gu</name>
      <address>
        <city>Soeul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Ujejskiego 75</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii, Aleja Zwyciestwa 31/32</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny S.A Przychondnia przy Łowieckiej, Łowiecka</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Madrid</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal, Carretera de Colmenar Viejo Km. 9100</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre, Avenida de Cordoba, s/n</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS, Paseo Castellana 261</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hosptial Regional Universitario de Malaga - Hospital General, Avenida Carlos Haya, s/n</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico, Paseo de San Vincent, 58</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio - PPDS</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia, Avda Fernando Abril Martorell no. 106</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

